11:10 AM EDT, 10/17/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and SystImmune said Friday that a phase 1 study of the antibody-drug conjugate iza-bren showed "promising" anti-tumor activity and "manageable" safety profile.

Presenting data at the European Society for Medical Oncology Congress in Berlin, the companies said the trial showed a 55% confirmed response rate among patients receiving the 2.5 mg/kg dose on days 1 and 8 every three weeks, with a median progression-free survival of 5.4 months.

"The encouraging activity observed with iza-bren in this early global study reinforce our confidence in its potential," said Anne Kerber, head of development, hematology, oncology and cell therapy at Bristol-Myers

Price: 43.14, Change: -0.25, Percent Change: -0.57